+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Global Hospital Pharmaceuticals Market: Rising Case of Chronic Conditions Drive Sales, Says TMR

Posted on Nov 04, 2016

The leading players in the global hospital pharmaceutical market held a share of 22.5% in 2014. The players, Novartis, Pfizer, Sanofi, Roche, and Merck & Co., have remained dominant in the overall market due to their well-planned, strategic partnerships with small and medium-sized local players to strengthen their pipeline. Furthermore, the development of new drugs will also help the companies remain relevant in the intense competition. “Shifting focus towards Asia Pacific will prove to be beneficial to the players in the global market as the region is undergoing a positive economic change that is characterized with rising disposable incomes and improving infrastructure,” states the lead author of the research report. 

Rising Number of Heart Patients Catapults Cardiovascular Segment to Forefront

According to the research report, the opportunity in the global hospital pharmaceuticals market is expected to be worth US$280.3 bn by the end of 2023 from US$197.3 bn in 2014. The global market is anticipated to progress at a CAGR of 3.9% during the forecast period of 2015 to 2023. The global market is likely to witness North America in the lead as the regional market is anticipated to expand at a CAGR of 3.4% during the forecast years. The recovery of the pharmaceutical industry in North America and the rising per capita spending on health care are expected to boost the regional hospital pharmaceuticals market in the coming few years. Amongst the various types of indications being treated by hospital pharmaceuticals, the cardiovascular segment is anticipated to gain notable traction in the next few years. The high prevalence of cardiovascular diseases is expected to boost this segment at a 0.8% CAGR during the forecast years.

Demand for Hospital Pharmaceuticals Soars as Patents Cliff

The growing incidents of accidents, traumas, and other emergencies have spiked the demand for specialty drugs in hospitals across the globe. Additionally, growing prevalence of pneumonia, malaria, AIDS, and tuberculosis have also triggered a significant uptake of hospital pharmaceuticals in recent years. The growing number of cancer cases have also accelerated the consumption of hospital pharmaceuticals. The oncology segment includes drugs such as alkylating agents, anti-metabolites, hormonal agents, and immunomodulating agents. These pharmaceuticals are used for treating lung, breast, colorectal, and prostate cancer. A sudden jump in the number patients suffering from cardiovascular diseases has also augmented the demand for related hospital pharmaceuticals. All in all, growing cases of chronic conditions are responsible to the rising consumption of these pharmaceuticals

The looming patent expiry for blockbuster drugs such as Lyrica (pregabalin), Nucynta (Tapentadol), Avastin (bevacizumab), and Alimta (Pemetrexed) has created a promising ground for the entry of generic drugs. This emerging trend is expected to improve the affordability of several hospital pharmaceuticals for the low-income groups and thus result in increased spending. The high adoption rate of telemedicine technology across the healthcare sector to reach out of patients in remote locations has also proved to be a critical growth factor for the global hospital pharmaceutical market.

Preference for Home Care Reduces Chances for Sale of Hospital Pharmaceuticals

Though a perspective suggests that patent expirations could benefit the overall market, it is also logical to conclude that patent cliff could result in reduced sales and thus lesser revenues for certain drugs. Significant patent expirations are likely to hamper the global market during the forecast period. Furthermore, growing preference for home care has reduced hospital visits to a large degree, which has made a noticeable negative impact on the demand for hospital pharmaceutical in recent years.

The review is based on Transparency Market Research’s report, titled “Hospital Pharmaceuticals Market -  Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”

The report segments the market as:

  • Cardiology
    • Anti-hypertensives
    • Dyslipidemia drugs
    • Others
  • Oncology
    • Alkylating Agents
    • Anti-metabolites
    • Hormonal Agents
    • Immunomodulating Agents
    • Miscellaneous Drugs
  • Nephrology and Urology
    • Diuretic Agents
    • Anti-hypertensive Agents
    • Phosphate Binders
    • Anticholinergic Drugs
    • 5-Alpha Reductase Inhibitors
  • Neurology
    • Anti-anxiety Agents
    • Anti-migraine Drugs
    • Antidepressant Drugs
    • Anti-psychotic Drugs
  • Pain
    • Anticonvulsant Drugs
    • Anesthetic Drugs
    • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Opioids
    • Non-narcotics Analgesic Drugs
  • Infection
    • Antibacterial Drugs
    • Antiviral Drugs
    • Antifungal Drugs
    • Antiparasite Drugs

Global Hospital Pharmaceuticals Market, by Indication

  • Cardiology
    • Coronary Heart Diseases
    • Stroke
    • High Blood Pressure
    • Heart Failure
    • Others
  • Oncology
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others
  • Nephrology and Urology
    • Acute Kidney Failure
    • Chronic Kidney Diseases
    • Glomerular Diseases
    • Diabetes
    • Others
  • Neurology
    • Epilepsy
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Others
  • Pain
    • Neuropathic Pain
    • Fibromyalgia
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Cancer Pain
  • Infection
    • Tuberculosis
    • Pneumonia
    • Hepatitis A
    • Hepatitis B
    • Candida Infection
    • Fungal Meningitis
    • Shigellosis
    • Amoebiasis
    • Other

Global Hospital Pharmaceuticals Market, by Geography

  • North America
    • U.S
    • Canada
  • Asia Pacific
    • China
    • Japan
    • Rest of APAC
  • Europe
    • UK
    • Germany
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Rest of the World

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Back To Top